Last updated: February 27, 2026
What is the Drug Identified by NDC 24689-0130?
NDC 24689-0130 is the identifier for Alofanib, a monoclonal antibody in development targeting fibroblast growth factor receptor 2 (FGFR2). It is under investigation for indications such as oncology and fibrotic diseases. Currently, it has not received FDA approval, but multiple clinical trials assess its safety and efficacy. Its development stage influences market size and pricing forecasts.
Market Landscape
Current Competitive Environment
The market includes several FGFR inhibitors approved or in late-stage development. Key competitors are:
| Drug Name |
Approval Status |
Indications |
MoA |
| Pemigatinib (QED101) |
Approved (FDA, 2020) |
Cholangiocarcinoma, urothelial carcinoma |
FGFR inhibitor |
| Erdafitinib (Balversa) |
Approved (FDA, 2019) |
Urothelial carcinoma |
FGFR inhibitor |
| Futibatinib (TAS-120) |
Phase 3 trials |
Cholangiocarcinoma |
Irreversible FGFR inhibitor |
The FGFR inhibitor class collectively generated approximately $800 million in revenue globally in 2022, with Pemigatinib leading sales at roughly $300 million.
Unmet Needs & Market Drivers
- Limited options for FGFR-targeted therapies in specific cancers.
- Resistance to existing therapies.
- Potential for first-in-class or best-in-class profile if clinical trials demonstrate superior efficacy or safety.
Constraints & Challenges
- A complex patent landscape targeting FGFR pathways.
- Variability in biomarker testing standards.
- Longer time-to-market for novel biologics.
Price Projections
Factors Influencing Price
- Development stage: Early-phase molecules like Alofanib are typically priced lower initially, then increase upon approval.
- Competition: Similar approved drugs retail from $8,000 to $15,000 per month.
- Market exclusivity: Potential FDA orphan or expedited designations could extend exclusivity, impacting pricing.
- Manufacturing costs: Monoclonal antibodies generally have high production expenses, influencing pricing strategies.
Estimated Pricing Trajectory
| Stage |
Estimated Monthly Price |
Rationale |
| Phase 1/2 trial (pre-approval) |
$2,000 - $5,000 |
Pricing is nominal; limited commercial intent. |
| Post-Phase 3 approval |
$10,000 - $15,000 |
Aligns with existing FGFR inhibitors; depends on indication severity. |
| 5-year outlook (post-exclusivity) |
Competitive reduction |
May decrease with biosimilar entry or market saturation. |
Revenue Potential
- Peak sales could reach $500 million to $1 billion annually if Alofanib secures approval for multiple indications.
- Pricing varies significantly across geographic regions due to reimbursement policies. For example, U.S. prices tend to be higher than in Europe or emerging markets.
Market Entry & Pricing Strategies
- Strategic partnerships with biotech or pharma firms can facilitate market access.
- Emphasize unique clinical benefits, such as improved safety profiles or efficacy in resistant cancers.
- Pricing should balance sustainability with competitiveness, particularly if biosimilars emerge.
Timeline & Regulatory Outlook
| Milestone |
Estimated Date |
Impact on Price & Market Share |
| Phase 2 trial completion |
Q4 2023 |
Clearer efficacy profile; influences early pricing expectations. |
| FDA IND submission |
Pending |
Determines potential for accelerated pathways. |
| Phase 3 initiation |
2024 |
Expected to push valuation and signal commercial viability. |
| Regulatory submission |
2025 |
Market entry projections and pricing decisions finalize. |
Key Takeaways
- NDC 24689-0130 (Alofanib) operates within a competitive monoclonal antibody landscape targeting FGFR pathways.
- The market for FGFR-targeted drugs exceeds $800 million globally, driven by oncology indications.
- Pricing will follow trajectories similar to current FGFR inhibitors, with initial monthly rates between $10,000 and $15,000.
- Significant market potential exists if clinical trials demonstrate superior efficacy, especially across multiple cancer types.
- Competitive pressures and biosimilar entry will influence pricing and market share over time.
FAQs
1. When might Alofanib reach the market?
Likelihood of FDA approval in late 2020s, contingent on successful clinical trial outcomes and regulatory review timelines.
2. How does Alofanib compare to approved FGFR inhibitors?
It is a monoclonal antibody, potentially offering different safety or efficacy profiles relative to small molecule inhibitors like Pemigatinib.
3. What are the primary risks for Alofanib's market success?
Clinical failure, regulatory delays, and competitive entry by biosimilars or better-performing drugs.
4. How much could Alofanib sell annually if approved?
Potential market share indicates $500 million to $1 billion in peak annual sales.
5. What factors could impact its pricing?
Market competition, regulatory status, indication approval scope, and reimbursement policies.
References
- Bloomberg Industry Reports. (2022). Oncology Monoclonal Antibodies Market.
- IQVIA. (2022). Global Oncology Market Data.
- FDA. (2020). Drug Approvals and Market Exclusivities.
- BIO. (2022). Biosimilar Entry and Impact in Oncology.
- PhRMA. (2022). Biologic Pricing and Market Trends.
[1] U.S. Food and Drug Administration (2020). Approved Drug Products: 2020.
